Get the Stockscreener App
12.91
0.04%
-0.0058
Alvotech stock is traded at $12.91, with a volume of 6,562.
It is down -0.04% in the last 24 hours and up +4.99% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
See More
Previous Close:
$12.92
Open:
$12.92
24h Volume:
6,562
Relative Volume:
0.05
Market Cap:
$3.89B
Revenue:
$306.77M
Net Income/Loss:
$-618.38M
P/E Ratio:
-6.5554
EPS:
-1.97
Net Cash Flow:
$-343.00M
1W Performance:
-0.35%
1M Performance:
+4.99%
6M Performance:
-10.32%
1Y Performance:
+45.43%
1-Day Range:
$12.88
$12.96
1-Week Range:
$12.58
$13.30
52-Week Range:
$8.39
$18.00
Alvotech Stock (ALVO) Company Profile
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for its biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA - Pharmaceutical Technology
Alvotech application for Simponi biosimilar accepted by EMA - MSN
Alvotech’s AVT05 Biosimilar Application Accepted by EMA - TipRanks
European Medicines Agency Confirms Acceptance of Marketing - GlobeNewswire
Alvotech to Report Financial Results for the First Nine - GlobeNewswire
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - Yahoo Finance UK
Alvotech, Teva obtain FDA nod for new Selarsdi indication - Drug Store News
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - StockTitan
Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire
FDA approves Alvotech and Teva’s SELARSDI for new indications - MSN
Alvotech's SWOT analysis: biosimilar powerhouse stock faces growth hurdles - Investing.com
Teva, Alvotech get expanded FDA approval for Stelara biosimilar - MSN
Teva, Alvotech get expanded FDA approval for Stelara biosimilar (NYSE:TEVA) - Seeking Alpha
Alvotech and Teva Secure FDA Approval for SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - The Manila Times
Teva, Alvotech announce U.S. FDA approval of presentation of SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional - GlobeNewswire
Alvotech (NASDAQ:ALVO) Short Interest Update - MarketBeat
Generics Bulletin | Insights on Off-Patent and Generic Medicines | Insights - Citeline
Alvotech Advances With EU Application Acceptance - TipRanks
Alvotech application for Prolia/Xgeva biosimilar accepted by EMA (NASDAQ:ALVO) - Seeking Alpha
ALVOAlvotech Ordinary Shares Latest Stock News & Market Updates - StockTitan
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - The Manila Times
Marshall Wace LLP Decreases Holdings in Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech Announces European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, Proposed Biosimilar to Prolia and Xgeva - Marketscreener.com
Wall Street SWOT: Alvotech stock rises as biosimilar powerhouse gains momentum - Investing.com India
Wall Street SWOT: Alvotech stock rises as biosimilar powerhouse gains momentum By Investing.com - Investing.com South Africa
Alvotech (ALVO) Stock Price Up 3.79% on Sep 27 - GuruFocus.com
Alvotech (NASDAQ:ALVO) Shares Sold by Sculptor Capital LP - MarketBeat
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® - GlobeNewswire
Alvotech Initiates Confirmatory Patient Study for AVT16 - Marketscreener.com
Alvotech : Registration Statement Declared Effective - Marketscreener.com
EMA Accepts Marketing Authorization Application For Alvotech's AVT06 (Aflibercept) - Marketscreener.com
Alvotech (NASDAQ:ALVO) Short Interest Up 108.1% in August - MarketBeat
Alvotech : Filing of a Request with the SEC - Marketscreener.com
EMA Accepts Marketing Authorization Application for Alvotech’s AVT06 (aflibercept) - JD Supra
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewswire
Alvotech: Steady Progress Offers Good Chance Of Upside (ALVO) - Seeking Alpha
Alvotech : Filing of a Preliminary Prospectus with the SEC - Marketscreener.com
Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024 - The Center for Biosimilars
Alvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023) - Simply Wall St
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):